Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $664.5 million.

  • Ligand Pharmaceuticals' Cash & Current Investments rose 20254.64% to $664.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $664.5 million, marking a year-over-year increase of 20254.64%. This contributed to the annual value of $256.2 million for FY2024, which is 5041.19% up from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Cash & Current Investments is $664.5 million, which was up 20254.64% from $245.0 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Cash & Current Investments registered a high of $664.5 million during Q3 2025, and its lowest value of $121.4 million during Q3 2022.
  • Its 5-year average for Cash & Current Investments is $262.4 million, with a median of $226.9 million in 2024.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Cash & Current Investments tumbled by 6273.09% in 2021, and later surged by 20254.64% in 2025.
  • Ligand Pharmaceuticals' Cash & Current Investments (Quarter) stood at $341.1 million in 2021, then plummeted by 37.89% to $211.9 million in 2022, then decreased by 19.62% to $170.3 million in 2023, then soared by 50.41% to $256.2 million in 2024, then soared by 159.41% to $664.5 million in 2025.
  • Its Cash & Current Investments stands at $664.5 million for Q3 2025, versus $245.0 million for Q2 2025 and $208.9 million for Q1 2025.